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 Reversion of Steatosis by SREBP-1c Antisense 
Oligonucleotide did not Improve Hepatic Insulin 
Action in Diet-induced Obesity Mice
 NAFLD is associated with insulin resistance and 
hyperinsulinemia. Considering the fact that NAFLD 
patients often have a feature of metabolic syndrome 
such as insulin resistance and diabetes  [ 4 ] , this dys-
function deserves to be better investigated. The 
insulin receptor (IR) is a protein with endogenous 
tyrosine kinase activity that,  following  activation by 
insulin, undergoes rapid  auto phosphorylation and, 
subsequently, phosphorylates intracellular protein 
substrates, including insulin receptor substrate (IRS) 
1 and 2  [ 5 ,  6 ] . After stimulation by insulin, IRS1 and 
IRS2 associate with several proteins, including 
phosphatidylinositol 3-kinase (PI3K). Downstream 
from PI3K, the serine threonine kinase, Akt, is acti-
vated and plays a pivotal role in the regulation of 
various biological processes  [ 7 ,  8 ] . There is a current 
consensus that insulin resistance is caused by 
defects in intracellular insulin signaling, and several 
causes have been proposed to justify how the insu-
lin signaling defects are present in NAFLD subjects 
 [ 9 ] . Intake of high fat diet and accumulation of hepa-
tocellular lipids activate the 2 main infl ammatory 
 Introduction
 ▼
 Nonalcoholic fatty liver disease (NAFLD) is an 
expanding clinical entity and is considered the 
most common liver disorder in Western coun-
tries  [ 1 ] . The spectrum of the disease covers stea-
tosis to steatohepatitis that can evolve to 
cirrhosis, the end-stage liver disease. NAFLD is 
associated with genetics and environmental fac-
tors, such as sedentarism, high fat diet, and obes-
ity. In the liver, the transcription factor SREBP-1c, 
the crucial transcription factor responsible for 
lipogenesis, regulates the production of lipids, 
inducing the transcription of almost all the genes 
that encode enzymes involved in fatty acid syn-
thesis and esterifi cation of fatty acids to triglyc-
erides  [ 2 ] . Previous studies by our group 
demonstrated that the blocking of SREBP-1c by 
antisense oligonucleotide (ASO) decreased pro-
tein levels of lipogenic enzymes, reducing total 
liver fat accumulation and, fi nally, reversing 
hepatic steatosis in mice  [ 3 ] .
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 Abstract
 ▼
 The literature has associated hepatic insulin 
action with NAFLD. In this sense, treatments 
to revert steatosis and improve hepatic insu-
lin action become important. Our group has 
demonstrated that inhibition of Sterol Regula-
tory Element Binding Proteins-1c (SREBP-1c) 
reverses hepatic steatosis. However, insulin sig-
nals after NAFLD reversion require better inves-
tigation. Thus, in this study, we investigated 
if the reversal of NAFLD by SREBP-1c inhibitor 
results in improvement in the hepatic insulin 
signal in obesity mice. After installation/achieve-
ment of diet-induced obesity and insulin resist-
ance, Swiss mice were divided into 3 groups: 
i) Lean, ii) D-IHS, diet-induced hepatic steatosis 
[no treatment with antisense oligonucleotide 
(ASO)], and iii) RD-IHS, reversion of diet-induced 
hepatic steatosis (treated with ASO). The mice 
were treated with ASO SREBP-1c as previously 
described by our group. After ASO treatment, one 
set of animals was anesthetized and used for in 
vivo test, and another mice set was anesthetized 
and used for histology and Western blot analysis. 
Reversion of diet-induced hepatic steatosis did 
not change blood glucose, glucose decay con-
stant (k ITT ), body weight, or serum insulin levels. 
In addition, results showed that the protocol did 
not improve insulin pathway signaling, as con-
fi rmed by the absence of changes in IR, IRS1, Akt 
and Foxo1 phosphorylation in hepatic tissue. In 
parallel, no alterations were observed in proin-
fl ammatory molecules. Thus, our results suggest 
that the inhibition of SREBP-1c reverts steatosis, 
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pathways that impair the action of insulin; JNK and IKK/NFκB. 
Together, JNK and IKKβ might serve as an inhibitor of insulin signal-
ing, by inducing inhibitory serine 307 (Ser307) phosphorylation of 
IRS1  [ 10 ] . IKK is a serine kinase, and its activation phosphorylates 
the inhibitor of kappaB (IκB). After phosphorylation, IκB is ubiquiti-
nated and degraded in the proteaosome, releasing nuclear factor κB 
(NFκB) for the translocation to the nucleus and activation of gene 
expression  [ 11 ] . It has been proposed that increased NFκB activation 
may play an important role in the pathogenesis of insulin resistance 
 [ 12 ] .
 Hepatic lipid accumulation leads to insulin resistance. However, 
the reduction in liver lipids to result in improved hepatic insulin 
resistance needs further investigation. Based on the premises 
that accumulation of hepatocellular lipids is linked with insulin 
resistance in NAFLD, we hypothesized that blocking the SREBP-
1c reverse steatosis may improve the molecular insulin pathway 
and reduce hepatic insulin resistance. In this sense, the aim of 
the present study was to evaluate whether a reversion of diet-
induced hepatic steatosis by ASO SREBP-1c improves hepatic 
insulin resistance in obese mice.
 Materials and Methods
 ▼
 Animals and diet
 Male, 4-week-old Swiss mice were obtained from our breeding 
colony (UNESC) and maintained on a 12-h artifi cial light-dark 
cycle and housed in individual cages. The investigation followed 
the University guidelines for the use of animals in experimental 
studies. After the acclimatizing period (3 days), the animals 
were randomly divided into 2 groups; control mice (Lean) fed on 
standard rodent chow and obese mice, fed on a high-fat diet for 
2 months (DIO). Eight weeks of fat-rich diet feeding was set as 
the time by which all mice should have developed obesity  [ 13 ] . 
After installation/achievement of diet-induced obesity, mice 
were divided in 2 groups: D-IHS, diet-induced hepatic steatosis 
(no treatment with ASO), and RD-IHS, reversion of diet-induced 
hepatic steatosis (treated with ASO). The mice were treated 
intraperitoneally with ASO SREBP-1c (3 nmol/day) for 14 days 
concurrently with a high-fat diet, as described by Frederico and 
colleagues  [ 3 ] . One set of animals was anesthetized and used for 
in vivo test, and another mice set was anesthetized and used for 
histology and Western blot analysis.
 Hormone and biochemical measurements
 Serum insulin and TNFα were measured by ELISA kit (Crystal 
Chem Inc., Chicago, IL). Blood glucose was measured by glu-
cosimeter.
 Intraperitoneal insulin tolerance test (ipITT)
 Insulin (2 U/kg body weight) was injected via i.p. and blood sam-
ples were collected from the tail at 0, 5, 10, 15, 20, 25, and 30 min 
for blood glucose determination. The constant rate for glucose 
disappearance (k ITT ) was calculated using the formula 0.693/t 1/2 . 
Glucose t 1/2 was calculated from the slope of the least-square 
analysis of the plasma glucose concentrations during the linear 
decay phase  [ 13 ] .
 Protein analysis by immunoblotting
 As soon as anesthesia was assured by the loss of pedal and cor-
neal refl exes, the abdominal cavity was opened. For analysis of 
the insulin pathway, mice were opened and the animals received 
an injection of insulin ( + ) (100 μl, 10  − 6 mol/l) or saline ( − ) 
(100 μl) through the cava vein. Afterwards, fragments of hepatic 
tissue were excised. For proinfl ammatory analysis insulin was 
not injected. The tissues were homogenized immediately in 
extraction buff er at 4 °C with a Polytron MR 2100 (Kinematica, 
Switzerland), operated at maximum speed for 30 s. The extracts 
were centrifuged at 11 000 rpm and 4 °C (5804R) (Eppendorf AG, 
Hamburg, Germany) for 40 min to remove insoluble materials, 
and the supernatants were used for protein quantifi cation, using 
the Bradford method  [ 14 ] and proteins were denaturated by 
boiling in Laemmli  [ 15 ] sample buff er containing 100 mM DTT. 
Then, 0.2 mg of protein extract obtained from each sample was 
separated by SDS-PAGE, transferred to nitrocellulose mem-
branes and blotted with anti-IR, anti-IRS1, anti-Akt, anti-
phospho[Ser473]Akt, anti-Foxo1, anti-β-actin, anti-phospho
-JNK, anti-JNK, anti-TLR2, anti-MyD88, anti-NFκB, and anti-IKKβ 
antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA); and 
anti-phospho-Foxo1, anti-phospho-IR, anti-phospho-IKKβ, anti-
TNFα, anti-IL-1β antibodies (Cell Signaling Technology, Beverly, 
MA, USA). The original membrane was stripped and reblotted for 
total protein levels and β-actin loading protein. Chemilumines-
cent detection was performed with horseradish peroxidase-con-
jugate secondary antibodies. Autoradiographs of membranes 
were taken for visualization of protein bands. The results of blots 
are presented as direct comparisons of bands in autoradiographs 
and quantifi ed by densitometry using the Scion Image software.
 Histology
 Hydrated, 5.0 μm sections of paraformaldehyde-fi xed, paraffi  n-
embedded liver fragments of 4 mice were stained with hema-
toxylin/eosin and photodocumented using an Olympus BX60 
microscope.
 Statistical analysis
 Results are expressed as the means ± SEM. Diff erences between 
the groups were evaluated using one-way analysis of variance 
(ANOVA). When the ANOVA indicated signifi cance, a Bonferroni 
post hoc test was performed. A probability of less than 0.05 was 
considered signifi cant. The software used for analysis of the data 
was the Statistical Package for the Social Sciences (SPSS) version 
17.0 for Windows.
 Fig. 1  Hematoxylin/eosin staining in the liver of 
Lean, D-IHS, and RD-IHS mice. Hematoxylin/eosin 
staining of 5.0 μm sections of livers (n = 4) was 
performed to confi rm effi  ciency of diet for induce 
hepatic steatosis (D-IHS) and ASO treatment to 
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 Results
 ▼
 Diet-induced hepatic steatosis was used in the present study, 
since studies performed by our group have demonstrated it ear-
lier  [ 3 ,  16 ,  17 ] . On the other hand, our group has proved the 
reversion of steatosis using the ASO technique anti-SREBP-1c 
 [ 3 ] . Thus, in the present study we used ASO SREBP-1c for rever-
sion of diet-induced hepatic steatosis (  ●  ▶   Fig. 1 ).
 The next step was to evaluate the eff ect of reversion of steatosis 
on metabolic and physiological parameters.   ●  ▶   Table 1 shows 
comparative data regarding lean, D-IHS, and RD-IHS mice. The 
D-IHS mice had a higher body weight, epididymal fat, serum 
insulin, blood glucose, serum TNFα, and a lower glucose disap-
pearance than age-matched controls. In RD-IHS mice these 
parameters were not altered (  ●  ▶   Table 1 ). The results of serum 
insulin, blood glucose and k ITT (  ●  ▶   Table 1 ) suggested that the 
reversion of diet-induced hepatic steatosis model (  ●  ▶   Fig. 1 ) is 
not suffi  cient to alter the insulin resistance. There was no sig-
nifi cant diff erence in food intake in the group treated with anti-
sense SREBP-1c (data not shown).
 The insulin signaling was examined in the liver of D-IHS mice. 
High-fat diet reduced IR and IRS1 phosphorylation (  ●  ▶   Fig. 2a, b , 
respectively). Reversion of steatosis did not result in signifi cant 
changes in IR and IRS1 phosphorylation. In addition, D-IHS mice 
demonstrated reduced Akt ser473 phosphorylation, when com-
pared with the lean mice (  ●  ▶   Fig. 2c ). Results of equal magnitude 
occur in the phosphorylation of Foxo1 (  ●  ▶   Fig. 2d ). As a result of 
the sequence of the state of insulin resistance described above 
(k ITT ), in the livers of the RD-IHS group, Akt ser473 and Foxo1 phos-
phorylation did not change (  ●  ▶   Fig. 2c, d ). No diff erences were 
observed in the basal (no insulin) levels of either Akt ser473 or 
Foxo1 phosphorylation between the groups. The IR, IRS1, Akt, 
and Foxo1 protein levels did not diff er between the groups 
(  ●  ▶   Fig. 2a–d , lower panels).
 To verify why the fatty liver does not alter resistance to insulin, 
we analyzed infl ammatory protein expression. The high-fat diet 
induced an increase the cytokine TNFα and IL-1β, when com-
pared with Lean group. The use of SREBP-1c inhibitor reverts 
steatosis but not alter the protein levels of these cytokines 
(  ●  ▶   Fig. 3a, b ). Toll like receptor 2 (TLR2) is a crucial receptor acti-
vated to infl ammatory signal and saturated fatty acids through 
their molecule adaptator MyD88. Livers of the obese mice 
showed increased protein levels of TLR2 and MyD88, when com-
pared with Lean group (  ●  ▶   Fig. 3c upper and lower panels, 
respectively). Steatosis reversion does not change protein levels 
of TLR2 and MyD88. The high-fat diet increased both IKKβ phos-
phorylation and NFκB protein levels, when compared to the lean 
diet (  ●  ▶   Fig. 3d, e ). Reversion of diet-induced hepatic steatosis 
does not cause signifi cant changes in either IKKβ phosphoryla-
tion or NFκB protein levels, when compared with respective 
D-IHS mice (  ●  ▶   Fig. 3d, e ). The high-fat diet induced an increase 
JNK phosphorylation in the liver of D-IHS mice, when compared 
with lean mice (  ●  ▶   Fig. 3f ). In RD-IHS mice signifi cant changes in 
JNK phosphorylation were observed (  ●  ▶   Fig. 3f ).
 Table 1  Metabolic characteristics. 
  Lean  D-IHS  RD-IHS 
 Body weight (g)  39.3 ± 2.0  53.4 ± 1.9*  51.6 ± 1.7* 
 Epididymal fat ( %/b.w.)  1.0 ± 0.2  4.3 ± 0.3*  4.1 ± 0.5* 
 Insulin (ng/ml)  2.0 ± 0.6  12.3 ± 2.5*  11.9 ± 3.1* 
 Blood glucose (mmol/l)  5.8 ± 0.4  11.1 ± 0.7*  10.7 ± 0.7* 
 k ITT ( %/min)  4.0 ± 0.9  2.3 ± 0.4*  2.6 ± 0.6* 
 TNFα (pg/ml)  4.0 ± 1.5  31.8 ± 6.1*  29.7 ± 7.2* 
 Symbols represent statistical signifi cance. n = 8, *p < 0.05 D-IHS and RD-IHS groups 
when compared with Lean mice 
 Fig. 2  *p < 0.05 Lean group with insulin  injection 
(+) when compared with Lean mice (−), and 
# p < 0.05; RD-IHS  and D-IHS groups (+) when 
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 Discussion
 ▼
 Hepatic insulin resistance is associated with NAFLD and is a 
major factor in the pathogenesis of type 2 diabetes mellitus and 
metabolic syndrome  [ 18 ,  19 ] . In NAFLD, fat accumulation in the 
liver may occur as a result of increased fat deposition, increased 
fat synthesis and reduced fatty acid oxidation  [ 20 ] . Scientifi c 
advances have identifi ed possible molecular mechanisms related 
to the onset of steatosis. In this sense, some studies have shown 
that the accumulation of fat in the liver is associated with high 
levels of SREBP-1c protein  [ 20 – 22 ] . Our group has previously 
demonstrated that inhibition of SREBP-1c by ASO results in 
decreased protein levels of the lipogenic enzymes, reduction of 
69 % in total liver fat and, fi nally, a reversion of hepatic steatosis 
in obese mice  [ 3 ] . However, hepatic insulin action in this model 
of reversion steatosis has not been described. With this in mind, 
we evaluated whether the reversion of steatosis by SREBP-1c 
inhibitor improves hepatic insulin action in obese mice.
 In the present study, we observed that high-fat diet leads to reduc-
tion in whole body insulin sensitivity (k ITT ), elevated blood glucose 
levels, serum insulin, epididymal fat, and serum TNFα. On the other 
hand, the use of ASO reverted steatosis in RD-IHS group, but no 
improvement in systemic insulin sensitivity; demonstrated by the 
absence of changes in disappearance of glucose, blood glucose, and 
serum insulin. In addition, no change was observed in body weight 
and epididymal fat. Thus, our data indicate that the reduction in int-
rahepatic lipids alone was not an eff ective treatment of systemic 
insulin resistance. More recently, Moon et al.  [ 23 ] have found similar 
data; the authors also showed that elimination of nuclear SREBPs in 
liver ameliorates pathologic triglycerides accumulation in diff erent 
experimental models, but they reported that the reduced hepatic 
fatty acid overproduction is not required for the development of sys-
temic insulin resistance in mice, since hepatic resistance to insulin 
action was not recovered. Taken together, our results suggest that 
other alterations are necessary for improvement of insulin resist-
ance, mainly such as reduced adiposity and infl ammation.
 Fig. 3  *p<0.05; RD-IHS  and D-IHS groups when 
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 Next, we analyzed the hepatic insulin action, through IR, IRS, 
Akt, and Foxo1 phosphorylation, in obese mice treated with ASO 
SREBP-1c. Hepatic tissue of obese mice showed reduced IR, IRS1, 
Akt, and Foxo1 phosphorylation. The treatment with ASO 
SREBP-1c reverses hepatic steatosis, but not altered the phos-
phorylation of these molecules. We suggest that the reversion of 
hepatic steatosis by ASO SREBP-1c did not reverse hepatic insu-
lin action because it does not reverse TNFα and proinfl amma-
tory molecules.
 The excess fat aff ects the integration of metabolic and immune 
response pathways. Recently, several studies have demonstrated 
that obesity is associated with low-grade chronic infl ammation 
that is causally involved in the development of insulin resistance 
 [ 24 ] . The negative impact of increased fat accumulation in sensi-
tivity to insulin can be clearly demonstrated in most subjects, as 
well as reduction in insulin resistance observed with weight 
loss. Infl ammation is markedly evident in a number of human 
and mouse models of obesity, as determined by increased of 
infl ammatory cytokines  [ 24 ] . The cytokine TNFα was the fi rst 
indication that infl ammatory mediators are associated with 
obesity  [ 25 ] . Moreover, the TNFα have been implicated in the 
development of insulin resistance  [ 26 ] . Our study showed that 
the use of ASO reverses steatosis, but it does not reduce adipos-
ity and serum levels of TNFα.
 One mechanism by which cytokines proinfl ammatory-induced 
by lipids induce insulin resistance is through active proinfl am-
matory molecules, including JNK and NFκB/IKK. Suppression of 
the JNK pathway in liver ameliorates insulin resistance status 
and glucose tolerance in both genetic and dietary models of dia-
betes  [ 27 ] . On the other hand, studies indicate that lipid accu-
mulation in the liver leads to hepatic infl ammation through 
NFκB activation and downstream cytokine production; this 
causes insulin resistance both in liver and systemically 
 [ 11 ,  28 ,  29 ] . Our results show that animals submitted to high-fat 
diet has pronounced increase of IKKβ phosphorylation and NFκB 
protein levels and, after treatment with ASO, no changes were 
observed these parameters.
 In the present study, we also examined the contribution of the 
toll like receptors (TRL2) upon infl ammatory response. The 
infl ammatory response in part, is mediated by toll like receptors, 
following by activation NFκB pathway. Studies have shown 
increased expression of key components of the innate immune 
cascade in states of obesity and diabetes mellitus type 2, in par-
ticular TLR2 and TLR4  [ 30 – 32 ] . In the present study, it was 
observed that TLR2 protein levels exhibited the same pattern of 
the other proteins involved in infl ammatory pathway.
 In summary, our results demonstrate that antisense oligonucle-
otide treatment attenuates the incidence of fatty liver, but not 
obesity or insulin resistance in DIO mice. The inhibition with 
ASO may represent a pharmacological treatment in humans 
after the establishment of disease, but when the objective is to 
reverse steatosis and also to reduce hepatic insulin resistance, 
other drugs should be associated.
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